Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT

Norishige Yoshikawa(Takatsuki General Hospital), Kandai Nozu(Kobe Children's Hospital), Ryojiro Tanaka(Kobe Children's Hospital), Koichi Nakanishi(University of the Ryukyus), Kazumoto Iijima(Kobe Children's Hospital), Yuko Shima(Wakayama Medical University), Hiroshi Hataya(Japanese Society for Dialysis Therapy), Kenji Ishikura(Kitasato University), Masataka Honda(Rikkyo University), Takeshi Matsuyama, Yoshitsugu Kaku(Fukuoka Children's Hospital and Medical Center for Infectious Diseases), Mayumi Sako(National Center For Child Health and Development)
Pediatric Nephrology
July 9, 2018
10.1007/s00467-018-4011-6
Cited by 35

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135